Introduction
PBMCs, monocytes may be enriched by several techniques.
Classically, the capacity of monocytes to adhere to plastic surfaces was employed to separate them from non-adherent lymphocytes [4] . More sophisticated technologies utilize magnetic beads coated with either anti-CD14 for the selection of monocytes [5, 6] or a combination of anti-CD2 and anti-CD19 antibodies for the depletion of T and B lymphocyte from monocytes [5, 7, 8] . More recently an elutriation procedure was introduced for monocyte enrichment from leucocyte apheresis products, which is based on a counter-flow centrifugation principle [9] [10] [11] [12] . All three technologies are semi-automated in-line procedures using clinical grade material. It seems therefore a reasonable and timely measure for manufacturers of DC cancer vaccines to start implementing one of these advanced monocyte enrichment technologies. [14, 15] . However, IL-12 secretion ceases 24 hrs after exposure to LPS/IFN-␥ [16] . Thus, a hallmark of our DC cancer vaccine technology is that we apply DCs as soon as 6 [17] .
Other aspects of DC manufacturing for clinical application concern the choice of a clinical grade culture medium that omits the use of bovine serum or the selection of a suitable maturation stimulus. In the majority of the recently conducted DC cancer vaccine trials, the DCs were exposed to a cytokine cocktail comprised of tumour necrosis factor (TNF)-␣, prostaglandin (PG) -E2, IL-1␤ and IL-6 [3]. Such DCs lack the capacity for IL-12 secretion and thus for effective type I polarization of an immune response that ultimately leads to the support of cytolytic immunity [13]. We, thus have developed a DC cancer vaccine technology platform that uses clinical grade lipopolysaccharide (LPS) and interferon (IFN)-␥ for DC maturation and has the capacity to trigger the release of IL-12

hrs after LPS/IFN-␥ activation enabling the release of IL-12 during DC/T-cell interaction
In a series of four clinical pilot trials for DC cancer vaccination we have so far treated more than 50 patients with paediatric and adult malignancies using a conventional protocol [17] [18] prompted us to change our DC manufacturing standard protocol also in our clinical trials. Analysing the first three DC cancer vaccines for patients indicated that the modified procedure was also suitable for patients resulting in the generation of DCs that fulfilled all quality as well as potency criteria. 
. The improvement in the enrichment of monocytes using elutriation, the successful implementation of a clinical grade DC culture medium, as well as optimizations of the LPS/IFN-␥ maturation using a clinical grade LPS preparation certified by the US Pharmacopeia for the use in human beings
Material and methods
Leucocyte apheresis
Monocyte enrichment
Monocytes were enriched by plastic adherence as described previously [17] 
IL-12 detection by ELISA
IL-12 concentrations in the supernatant of the DC cultures were measured as described previously [17] .
Allogeneic mixed leucocyte reactions
Stimulating DCs (10, 000, 2000 
Statistics
Statistical significance of all results was calculated by use of an unpaired Student's t-test. Results are given in mean Ϯ standard error of mean (SEM).
Results
Manufacturing of LPS/IFN-␥-activated dendritic cell-based cancer vaccines
We Fig. 1A ).
Leucocyte apheresis
We analysed leucocyte apheresis products from 11 selected healthy donors and three patients suffering from neoplastic diseases (Fig. 2). The three patients received a DC cancer vaccine, manufactured according to Fig. 1, in the course of a clinical trial that was approved by the institutional review board of the Medical
Recovery and purity of monocytes after enrichment
applied to the patients immediately after thawing and washing (Fig. 1A) . We therefore froze the smDCs and measured recovery and purity after thawing (Fig. 3) 
Recovery and purity of mature dendritic cells after 48 hrs of LPS/IFN-␥ activation
We re-cultivated smDCs recovered from freezing for 2 days and determined recovery and purity (Fig. 3) 
DC quality and potency control
According to the quality control protocol (Fig. 1A) Fig. 4A and B) . All DCs manufactured from monocytes enriched by the various procedures had a comparable capacity for T lymphocyte activation in an alloMLR (Fig. 4C) .
Optimization of conditions for LPS/IFN-␥ maturation
Based on this comparative evaluation of the different monocyte enrichment procedures, we implemented elutriation and the clinical grade medium in the SOP for the manufacturing of our DC cancer vaccine (Fig. 1A) . In order to confirm that this procedure is suitable for the manufacturing of an effective cancer vaccine, we further optimized the maturation with LPS/IFN-␥ together with the DC freezing step after 6 hrs (Fig. 5) (Fig. 1A) . We measured a recovery of 29 Ϯ 7% of smDCs with a mean purity of 88 Ϯ 1% (Fig. 6) 
Feasibility of DC cancer vaccine manufacturing for patients
We have so far treated more than 50 patients in four DC cancer vaccine pilot trials. In these trials we used the conventional adherence procedure to enrich patient's monocytes from leucocyte apheresis products. Based on the data above, we manufactured cancer vaccines for three patients following the novel SOP implementing elutriation and clinical grade DC medium
Discussion
DC-based cancer vaccines have the potential to become an independent module in the treatment of tumours supplementing the
Fig. 3 Recovery and Purity of LPS/IFN-␥ activated-DCs manufactured by using different monocyte enrichment protocols. Six hours (smDCs) and 48 hrs (mDCs) LPS/IFN-␥-activated iDCs were generated using monocytes from healthy individuals. Monocytes were enriched from leucocyte apheresis products by plastic adherence, CD14 selection, CD2/CD19 depletion or elutriation (as indicated) using AIM V/Octaplas or clinical grade CellGro DC Medium. Upper: The mean percentage Ϯ SEM of recovery of monocytes after enrichment, smDCs or mDCs, as indicated, is given relative to monocytes in the leucocyte apheresis product. Lower: The mean percentage Ϯ SEM of monocytes before and after enrichment, smDCs and mDCs, as indicated, is given relative to the total number of leucocytes. Number of independent DC preparations in AIM-V/Octaplas medium:
adherence, n ϭ 10; selection, n ϭ 5; depletion, n ϭ 9; elutriation, n ϭ 7; and CellGro DC medium: adherence, n ϭ 5, selection, n ϭ 3; depletion, n ϭ 2; elutriation, n ϭ 10. na, no data available; p, P Ͻ 0.01. 14, 15, 17, 19] . [14, 15] . The culture conditions for monocyte differentiation into DCs are well established and allow only minor modifications [20] [9] [10] [11] [12] . Using monoclonal antibodies two strategies are feasible: enrichment of monocytes using magnetic bead-coupled monoclonal antibodies selecting CD14 expressing monocytes [5, 6] ; or depleting CD2 or CD19 expressing [5, 7, 8] . All three techniques may be performed as an in-line procedure, which is a significant step towards GMP compliance and hence product safety. The immune phenotype, IL-12 secretion, and the stimulatory capacity of the DCs obtained by all methods were similar (Fig. 4) (Fig. 3) (Fig. 5) . For the manufacturing of a DC cancer vaccine for three patients according to a revised SOP (Fig. 1A) , we used a mean LPS concentration of 30 ng/ ml which induced a mature phenotype meeting our quality criteria (Fig. 6) .
standard treatment regime that includes surgery, chemotherapy and radiation therapy [1]. At the verge of widespread clinical application, it is mandatory that the safety of such pharmaceuticals is beyond doubt and that the manufacturing protocols guarantee the quality of the DC cancer vaccines. During the last years, we have continuously worked on the improvement of DC manufacturing using LPS/IFN-␥ as the activation stimulus [5,
By comparing different monocyte enrichment procedures in this study using leucocyte apheresis products from healthy individuals, we designed a new SOP for the manufacturing of clinically applied DCs implementing elutriation as the most effective enrichment procedure and a clinical grade culture medium that did not impair DC quality. The feasibility of our newly established protocol was confirmed by the manufacturing of LPS/IFN-␥-activated smDCs for the treatment of three cancer patients. The DCs complied with quality and potency criteria that have been defined according to previous in vitro studies
Fig. 4 DC quality control. Monocytes from healthy individuals were enriched from leucocyte apheresis products by different enrichment procedures, as indicated, differentiated into DCs followed by activation with LPS/IFN-␥. DC preparations using AIM-V/Octaplas or CellGro DC medium are combined. (A) The left-hand panel shows the ratio of increase in the expression density Ϯ SEM of the indicated DC maturation markers measured 6 hrs (smDCs) and 48 hrs (mDC) after activation. DCs generated from elutriated monocytes (number of preparations, n ϭ 35) are analysed. The right-hand panel compares the expression density mean fluorescence intensity (MFI) Ϯ SEM of maturation markers measured on mDCs that are generated from monocytes isolated by the indicated enrichment procedures. MFIs of the isotype controls are below 5 (data not shown). (B) Secretion of IL-12 Ϯ SEM secreted from mDCs analysed in (A) is illustrated. (C) Proliferation of allogeneic PBMCs in co-cultures with the DCs analysed in (A) is given relative to PBMCs stimulated with the super-antigen staphylococcal enterotoxin A/B (SEA/SEB) (normalized to 100%) and the background proliferation of unstimulated PBMCs (normalized to 0%). Number of preparations in (B) and (C)
:
T-and B lymphocytes from PBMCs
, identifying elutriation as the most favourable method for the manufacturing of DCs according to our technical requirements. Elutriation yielded the highest recovery of monocytes with purity only slightly lower as obtained with CD14 selection, the method that resulted in
Fig. 5 Optimization of DC maturation. Left-hand panels: Expression density (MFI) of the indicated DC membrane molecules and viability of mDCs as well as IL-12 secretion during the differentiation of smDCs into mDCs is shown after exposure to increasing concentrations of lipopolysaccharide (LPS) at constant IFN-␥ concentration. Data from two healthy donors are shown. Right-hand panel: LPS at a concentration of 30 ng/ml was applied for 6 hrs (ϩ) or the DCs were left immature (Ϫ) in the presence of IFN-␤. According to the DC-manufacturing protocol for cancer vaccines, DC cultures were frozen after 6 hrs in liquid nitrogen
After 
